Market and company headlines
Fred Alger Management, an investment management company, released its third-quarter 2026 investor letter for “Alger Small Cap Growth Fund”. The letter can be downloaded here. U.S. equities rose modestly in Q3 2026, with the S&P 500 up 2%, driven by strong earnings, consumer resilience, and AI investment—but gains were concentrated in a few large companies. Rising […]
Yahoo·10:54·21 Hours AgoADPT▲+0.5%
Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ADPT stock is a buy.
SeekingAlpha·06:16ADPT▲+0.5%
For questions about this article or underlying research, email help@trefis.com.
Yahoo·08:47
Tempus AI (TEM) stock has lost 17.3% over the past month, while the S&P 500 gained 0.6%. The company still grew sales 22% in its latest quarter, but the risk worth your attention lies with the few drugmakers that license its data. One of them is a very large client. Which drugmaker is it, and how long does its deal with Tempus AI run.
Yahoo·07:03
SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. East
Yahoo·16:05ADPT▲+0.5%
